According to our new research study on “PCR Technologies Market Forecast to 2030 – Global Analysis – by Technology, Offerings, Application, and End User,” the PCR technologies market size is expected to grow from US$ 13,101.87 million in 2022 to US$ 24,524.50 million by 2030; it is anticipated to register a CAGR of 8.2% from 2022 to 2030. Factors such as the rising prevalence of genetic and infectious diseases and surging investments and funds for PCR technologies propel the market growth. However, the high costs of PCR systems and the availability of alternative assays impede the PCR technologies market growth.
The global PCR technologies market is segmented by region into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. The North American regional market is expected to grow with a CAGR of 8.3% from 2022 to 2030. The North America PCR technologies market is segmented into the US, Canada, and Mexico. Market growth in this region is due to the increased demand for innovative products from bioanalytical instrument manufacturers and PCR companies, the presence of key market players, and extensive R&D conducted across various academic and research institutes. In addition, the well-known practice of adopting medical devices in healthcare operations to improve quality and reduce costs also benefits the PCR technologies market in the region.
PCR Technologies Market Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Technology (Real-Time PCR, Conventional PCR, Reverse Transcription PCR, Digital PCR, Multiplex RT PCR, Hot Start PCR, and Others), Offerings (Reagents and Consumables, Instruments, and Software and Services), Application (Gene Expression Analysis, Genetic Sequencing, Genotyping, Nucleic Acid Synthesis, Standard Validation, Point of Care Diagnostics, Environmental Application, and Others), End User (Hospitals and Diagnostic Centers, Academia and Research Institutes, Pharmaceutical and Biotechnology Companies, and Others), and Geography
PCR Technologies Market Drivers and Opportunities [2020-2030]
Download Free Sample
Rising Prevalence of Genetic and Infectious Diseases Drives the PCR Technologies Market
According to the National Organization's information on genetic conditions or congenital disabilities, genetic disorders are rare conditions, but they collectively comprise over 15,500 positive diagnoses every year. Estimates published in a report by MJH Life Sciences (US) in 2022 state that ~300,000 newborns are born with sickle cell disease (SCD) globally every year, accounting for ∼5% of the global population. In the US, SCD is one of the most prevalent genetic conditions. According to the Centers for Disease Control and Prevention (CDC), 1 in 500 African Americans is affected by an SCD, and ∼1 in 12 of them suffer from the autosomal recessive mutation. As per the June 2020 report by Novartis AG (Switzerland), ∼15,000 individuals and 270 newborns are diagnosed with SCDs every year. The disease is most prevalent in emerging nations such as India. Among India's tribal communities, ∼18 million people exhibit sickle cell traits (SCTs), and 1.4 million people are suffering from SCDs. As a result of the rising incidence of SCDs, the adoption of digital polymerase chain reaction (dPCR) is increasing in pathology centers, wherein this technology is being exploited for targeting various DNA-specific sequences to confirm diagnoses and design various clinical tests. dPCR can target specific DNA sequences in just one molecule of DNA. This tool allows researchers to detect rare genetic mutations that are difficult to identify using real-time PCR.
The COVID-19 outbreak had a substantial effect on the PCR technologies market. PCR is a nearly ubiquitous, robust, and reliable technology used in most molecular biology labs to amplify specific stretches of DNA for genotyping, cloning, and analysis of single nucleotide variations. The amplified DNA is the basis for most next-generation sequencing (NGS) preparations. Nearly all diagnostic tests used real-time PCR for testing people having symptoms of COVID-19. The majority of biotech and pharmaceutical businesses shifted their focus toward research and development divisions to find novel compounds or therapeutic approaches for COVID-19, which, in turn, benefitted the PCR technologies market. In February 2022, Roche added the Cobas 5800 System, a newly released molecular laboratory instrument, to its COVID-19 PCR portfolio for use in nations that accept the CE certification. These products include the Cobas SARS-CoV-2 and influenza A/B tests and the Cobas SARS-CoV-2 qualitative test. The product offers uniform performance and efficiency in low-, medium-, and high-volume molecular laboratory tests.
Applications Overview
Based on application, the PCR technologies market is segmented into gene expression analysis, genetic sequencing, genotyping, nucleic acid synthesis, standard validation, point of care diagnostic application, environmental application, and others. The gene expression analysis segment held a larger market share in 2022. Moreover, the same segment is anticipated to register a higher CAGR of 9.0% during 2022–2030.
Gene expression analysis examines how genes are recorded to synthesize functional gene products toward functional RNA species or protein products. The study of gene regulation helps in providing visions into normal cellular processes, such as differentiation and abnormal or pathological processes. Whole genome expression analysis mainly aims to identify cell or tissue phenotypes and discover new genes or signaling pathways involved in specific molecular processes and disease development. Researchers can perform gene expression analysis at one of the various levels at which the gene expression is regulated, namely transcriptional, post-transcriptional, translational, and post-translational protein modification.
Technology-Overview
Based on technology, the PCR technologies market is segmented into real-time PCR, conventional PCR, reverse transcription, digital PCR (dPCR), multiplex RT-PCR, hot start PCR, and others. The real-time PCR segment held the largest market share in 2022, and the same is expected to register the highest CAGR.
Real-time PCR is a nuclear-based approach for identifying specific genetic material in any disease, including viruses. Originally, radioactive isotope markers were used to detect specific genetic elements, but later improvement resulted in applying specialized markers, most often fluorescent dyes, to replace isotopic labeling. Real-time PCR has become one of the most extensively used methods of gene quantification. Because of its dynamic range, remarkable sensitivity, ability to be very sequence-specific, no post-amplification processing, and ability to increase sample throughput. Real-time RT-PCR is one of the most extensively used laboratory methods for detecting the COVID-19 virus. While several nations have used real-time RT–PCR to diagnose diseases, such as Ebola and Zika, many nations still require help applying this technology to the COVID-19 virus and extending their national testing abilities.
Competitive Landscape
Atila Biosystems, Thermo Fisher Scientific, Inc.; Takara Bio Inc.; Standard BioTools Inc.; F.Hoffmann-La Roche AG, Bio-Rad Laboratories, Inc; Agilent Technologies, BIOMERIEUX, QIAGEN, Promega Corporation; Becton, Dickinson and Company; Visby Medical, Inc.; and Ellume Limited are among the leading companies operating in the PCR technologies market. These companies emphasize new product launches and geographical expansions to meet the growing consumer demand worldwide, thereby increasing their product range in specialty portfolios. They have a widespread global presence, which helps them to serve a large set of customers and subsequently increase their market share.
Contact Us
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com